Artificial Immune Modulation Therapy Market Opportunity & Clinical Trials Insight 2026
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
'Artificial Immune Modulation Therapy Market Opportunity & Clinical Trials Insight 2026' Report Highlights:
Artificial Immune Modulation (AIM) is among the novel immunotherapy technologies that have been developed keeping in view the rising cases of cancer at global level. As every immunotherapy technology focuses on one major part of immune system, AIM technology’s working is also based on artificial antigen presenting cells (aAPC). AIM technology includes the engineering and administrating artificial antigen presenting cells to the patients which further is projected to mimic the core functions of natural antigen presenting cells present inside the human body.
The primary purpose with which artificial antigen presenting cells are administered to the patient involves antigen-specific recognition signal delivery by Major Histone Compatibility molecule loaded with an antigen peptide and also a co-stimulatory signal to direct action by the T cells. Development of another immunotherapy based treatment has caused an expansion of the field, where the contribution of immune cells against diseases is increasing exponentially. Targeting immune cells have projected a novel and regulated version of interaction between the diseased cells and immune system.
An important aspect of AIM therapy is that it provides satisfying nature for reinforcing the working mechanism of immune system against one target which includes the activation of specific types (antigen presenting cells and T-cells) in order to evoke a powerful immune response against specific antigen. It has been few decades since the development of immunotherapy for diseases in which immune system gets artificially activated, but few years since the discovery of AIM. Therefore, adding one more novel technology to this incredibly increases the access of eradicating cancer and other deadly cells from the body.
As per the research findings for analyzing the growing trends of artificial immune modulation, it has been observed that the therapy is prominent towards showing a data that is dominant. As the other immunotherapy products that are available for cancer such as Kymriah and Yescarta and their sales record establishes a hope that the arrival of novel products under AIM therapy will also establish a market that will be more inclined towards AIM. The growing cancer cases and the poor survival rate of other cancer therapies are driving the research world a little more dominant towards AIM.
Although the price of the therapy has not been decided yet but it has been estimated that the therapy will cost approximately the same as the other cancer immunotherapies. The therapy being novel is considered as a fast-growing method in the entire pharmaceutical industry. The therapy is still very young and is evaluated for causing a potential growth, substantive translational and clinical improvements. By observing the future outlook of the cancer cases and the current research activity, it is estimated that the market of AIM will undergo tremendous advancement leading towards the revolution of cancer therapeutics.
'Artificial Immune Modulation Therapy Market Opportunity & Clinical Trials Insight 2026' Report Highlights:
- Immunotherapy Inspired Design for Artificial Immune Modulation (AIM)
- Artificial Immune Modulations for Various Indications
- Clinical Trial Insight for AIM: 3 Drugs
- Expected Price Range for AIM Therapy: > US$ 250,000
- Market Potential During Five Years of Commercialization: > USD 500 Million
- Estimated Commercial Opportunity for Artificial Immune Modulation Drugs
- Future Directions for Artificial Immune Modulation
Artificial Immune Modulation (AIM) is among the novel immunotherapy technologies that have been developed keeping in view the rising cases of cancer at global level. As every immunotherapy technology focuses on one major part of immune system, AIM technology’s working is also based on artificial antigen presenting cells (aAPC). AIM technology includes the engineering and administrating artificial antigen presenting cells to the patients which further is projected to mimic the core functions of natural antigen presenting cells present inside the human body.
The primary purpose with which artificial antigen presenting cells are administered to the patient involves antigen-specific recognition signal delivery by Major Histone Compatibility molecule loaded with an antigen peptide and also a co-stimulatory signal to direct action by the T cells. Development of another immunotherapy based treatment has caused an expansion of the field, where the contribution of immune cells against diseases is increasing exponentially. Targeting immune cells have projected a novel and regulated version of interaction between the diseased cells and immune system.
An important aspect of AIM therapy is that it provides satisfying nature for reinforcing the working mechanism of immune system against one target which includes the activation of specific types (antigen presenting cells and T-cells) in order to evoke a powerful immune response against specific antigen. It has been few decades since the development of immunotherapy for diseases in which immune system gets artificially activated, but few years since the discovery of AIM. Therefore, adding one more novel technology to this incredibly increases the access of eradicating cancer and other deadly cells from the body.
As per the research findings for analyzing the growing trends of artificial immune modulation, it has been observed that the therapy is prominent towards showing a data that is dominant. As the other immunotherapy products that are available for cancer such as Kymriah and Yescarta and their sales record establishes a hope that the arrival of novel products under AIM therapy will also establish a market that will be more inclined towards AIM. The growing cancer cases and the poor survival rate of other cancer therapies are driving the research world a little more dominant towards AIM.
Although the price of the therapy has not been decided yet but it has been estimated that the therapy will cost approximately the same as the other cancer immunotherapies. The therapy being novel is considered as a fast-growing method in the entire pharmaceutical industry. The therapy is still very young and is evaluated for causing a potential growth, substantive translational and clinical improvements. By observing the future outlook of the cancer cases and the current research activity, it is estimated that the market of AIM will undergo tremendous advancement leading towards the revolution of cancer therapeutics.
1. ARTIFICIAL IMMUNE MODULATION NANOTECHNOLOGY OVERVIEW
1.1 Introduction to Artificial Immune Modulation Nanotechnology
1.2 Immunotherapy Inspired Design for Artificial Immune Modulation
1.3 Influence of Antigen Presenting Cells on T-cell Activation
2. ROLE OF NANOTECHNOLOGY IN ENRICHING ARTIFICIAL IMMUNE MODULATION PLATFORM
2.1 Nanoparticles Contributing to Other Immunotherapies Efficiency
2.2 Benefits Associated with Combining Nanotechnology to Artificial Immune Modulation
3. SYNTHETIC IMMUNOLOGY TO ENGINEER ANTIGEN PRESENTING CELLS
3.1 Synthetic Immunology for Already Available Immunotherapy
3.2 Eligibility & Applications of Synthetic Immunology in Artificial Immune Modulation
4. ARTIFICIAL IMMUNE MODULATIONS FOR VARIOUS INDICATIONS
4.1 Immunity - Cancer Cycle Relationship
4.2 Influence of Artificial Immune Modulation Over Cancer
4.3 Influence of Artificial Immune Modulation Against Other Indications
5. T-CELL ENRICHMENT & EXPANSION (E+E) TECHNOLOGY FOR PROPRIETARY ARTIFICIAL IMMUNE MODULATION PLATFORM
6. NEXIMMUNE CLINICAL TRIALS FOR ARTIFICIAL IMMUNE MODULATION PRODUCTS
6.1 NEX-001 & NEX-003 for Acute Myeloid Leukemia
6.1.1 Overview
6.1.2 Clinical Insight
6.2 NEX-002 for Multiple Myeloma
6.2.1 Overview
6.2.2 Clinical Insight
7. RECENT TRENDS & OPPORTUNITIES AVAILABLE FOR EXPANSION OF ARTIFICIAL IMMUNE MODULATION THERAPY
7.1 Globe Cancer Statistics
7.2 Increasing Popularity of Immunotherapy Treatments
7.3 High Adaptability by Pharmaceutical Companies
7.4 Immunotherapy in Combination with Other Cancer Treatment Methods
8. ESTIMATED COMMERCIAL OPPORTUNITY FOR ARTIFICIAL IMMUNE MODULATION DRUGS
8.1 Immunotherapies & Price Study for Estimating Artificial Immune Modulation Products Commercial Success
8.1.1 CAR-T Cell Therapy & their Products
8.1.2 Tumor-Infiltrating Lymphocyte Immunotherapy
8.2 AIM Therapy Price Estimates
9. DRIVERS & CHALLENGES TRIGGERED WITH THE OUTCOME OF ARTIFICIAL IMMUNE MODULATION
9.1 Drivers for Artificial Immune Modulation
9.2 Challenges for Artificial Immune Modulation
10. FUTURE DIRECTIONS FOR ARTIFICIAL IMMUNE MODULATION
10.1 Exploring New Avenues for Immunotherapy
10.2 Future Regional Landscape for Artificial Immune Modulation
11. Competitive Landscape
1.1 Introduction to Artificial Immune Modulation Nanotechnology
1.2 Immunotherapy Inspired Design for Artificial Immune Modulation
1.3 Influence of Antigen Presenting Cells on T-cell Activation
2. ROLE OF NANOTECHNOLOGY IN ENRICHING ARTIFICIAL IMMUNE MODULATION PLATFORM
2.1 Nanoparticles Contributing to Other Immunotherapies Efficiency
2.2 Benefits Associated with Combining Nanotechnology to Artificial Immune Modulation
3. SYNTHETIC IMMUNOLOGY TO ENGINEER ANTIGEN PRESENTING CELLS
3.1 Synthetic Immunology for Already Available Immunotherapy
3.2 Eligibility & Applications of Synthetic Immunology in Artificial Immune Modulation
4. ARTIFICIAL IMMUNE MODULATIONS FOR VARIOUS INDICATIONS
4.1 Immunity - Cancer Cycle Relationship
4.2 Influence of Artificial Immune Modulation Over Cancer
4.3 Influence of Artificial Immune Modulation Against Other Indications
5. T-CELL ENRICHMENT & EXPANSION (E+E) TECHNOLOGY FOR PROPRIETARY ARTIFICIAL IMMUNE MODULATION PLATFORM
6. NEXIMMUNE CLINICAL TRIALS FOR ARTIFICIAL IMMUNE MODULATION PRODUCTS
6.1 NEX-001 & NEX-003 for Acute Myeloid Leukemia
6.1.1 Overview
6.1.2 Clinical Insight
6.2 NEX-002 for Multiple Myeloma
6.2.1 Overview
6.2.2 Clinical Insight
7. RECENT TRENDS & OPPORTUNITIES AVAILABLE FOR EXPANSION OF ARTIFICIAL IMMUNE MODULATION THERAPY
7.1 Globe Cancer Statistics
7.2 Increasing Popularity of Immunotherapy Treatments
7.3 High Adaptability by Pharmaceutical Companies
7.4 Immunotherapy in Combination with Other Cancer Treatment Methods
8. ESTIMATED COMMERCIAL OPPORTUNITY FOR ARTIFICIAL IMMUNE MODULATION DRUGS
8.1 Immunotherapies & Price Study for Estimating Artificial Immune Modulation Products Commercial Success
8.1.1 CAR-T Cell Therapy & their Products
8.1.2 Tumor-Infiltrating Lymphocyte Immunotherapy
8.2 AIM Therapy Price Estimates
9. DRIVERS & CHALLENGES TRIGGERED WITH THE OUTCOME OF ARTIFICIAL IMMUNE MODULATION
9.1 Drivers for Artificial Immune Modulation
9.2 Challenges for Artificial Immune Modulation
10. FUTURE DIRECTIONS FOR ARTIFICIAL IMMUNE MODULATION
10.1 Exploring New Avenues for Immunotherapy
10.2 Future Regional Landscape for Artificial Immune Modulation
11. Competitive Landscape
LIST OF FIGURES
Figure 1-1: Natural Antigen Presentation by Antigen Presenting Cells
Figure 1-2: Artificial Immune Modulation Antigen Presentation
Figure 1-3: Types of Therapies Based on Immunotherapy Principle
Figure 1-4: Results of Antigen Presentation on T-Cells by Antigen Presenting Cells
Figure 1-5: US – Population of Men & Women Living with Auto-Immune Diseases (Million), 2020
Figure 1-6: US – Cancer Statistics (Million), 2019
Figure 2-1: Different Configurations Used in Nano Bio Materials for Medical or Biological Issues
Figure 2-2: Applications of Nanotechnology in Medicines
Figure 2-3: Potential Contribution of Nanoparticles to Immunotherapies
Figure 3-1: Synthetic Immunology Working on Immune Cells
Figure 3-2: Potential Addition of Functions to Engineered Immune Cells
Figure 3-3: Synthetic Immunology & Artificial Immune Modulation Combination
Figure 4 1: Representation of Immune System Attacking Cancer Cells with the help of Antigen Presenting Cells
Figure 4-2: North America – Population above 65 Years of Age (Million), 2018
Figure 4-3: Artificial Immune Modulation Against Cancer
Figure 4-4: US- Auto-Immune Diseases Statistics (Million), 2020
Figure 4-5: Potential Applications for Artificial Immune Modulation in Medical Field
Figure 5-1: Benefits of Clinical Trials in Medical World
Figure 5-2: Enrichment & Expansion Process Overview for Artificial Immune Modulation Platform
Figure 6-1: Ongoing Clinical Trials for Artificial Immune Modulation Platform by NexImmune
Figure 6-2: Robust Pipeline for Artificial Immune Modulation Products
Figure 6-3: US – Estimated Acute Myeloid Leukemia Statistics, 2020
Figure 6-4: US – Acute Myeloid Leukemia New Cancer Cases Statistics (%), 2020
Figure 6-5: US – Acute Myeloid Leukemia Deaths Statistics (%), 2020
Figure 6-6: US – Clinical Trial Status for Artificial Immune Modulation, 2020
Figure 6-7: US – Multiple Myeloma Cancer Statistics, 2020
Figure 6-8: US – Multiple Myeloma Cancer Statistics by Gender, 2020
Figure 6-9: US – Clinical Trial Status for Artificial Immune Modulation
Figure 7-1: Recent Trends & Opportunity for Artificial Immune Modulation Growth
Figure 7-2: Global – Total New Cases of Cancers (Million), 2018
Figure 7-3: Global - Total Cancer Deaths (Million), 2018
Figure 7-4: Global – New Cases of Multiple Myeloma, 2018
Figure 7-5: Global – Total Deaths Due to Multiple Myeloma, 2018
Figure 7-6: Clinical Benefits of using Cancer Immunotherapy
Figure 7-7: Global - Cancer Immunotherapeutic Market (US$ Billion), 2018-2026
Figure 7-8: US – Active, Not Recruiting Clinical Trials for Immunotherapy vs. Other Cancer Treatment Methods, 2020
Figure 7-9: Pharmaceutical Companies Investing in Immunotherapy Development
Figure 7-10: Global - Roche’s Total Immunological Products Sales (US$ Million), 2015 - 2019
Figure 7-11: Global – Roche Group Sales Increment (%), 2016 - 2019
Figure 7-12: Global – Eli Lilly’s Total Immunological Product Sales (US$ Million), 2017 - 2019
Figure 7-13: Global – Eli Lilly’s Increase in Immunology Revenue due to Taltz (%), 2018 & 2019
Figure 7-14: Potential Combinations for Artificial Immune Modulation
Figure 8-1: Global – CAR-T Cell Therapy Drug Kymriah Treatment Cost vs. Drug Cost (US$ Million), 2020
Figure 8-2: US – Price of CAR-T Cell Therapy Products (US$), 2020
Figure 8-3: Global – Kymriah Total Sales (US$ Million), 2018 & 2019
Figure 8-4: Global – Yescarta Total Sales (US$ Million), 2018 & 2019
Figure 8-5: US – TIL Immunotherapy Minimum & Maximum Treatment Price (US$), 2020
Figure 8-6: Immunotherapy Price Comparison
Figure 8-7: AIM Therapy – Minimum & Maximum Treatment Price Estimates (US$), 2026
Figure 9-1: Cancer Driver for Artificial Immune Modulation Market
Figure 9-2: Potential Drivers for Artificial Immune Modulation
Figure 9-3: Challenges Associated with Artificial Immune Modulation
Figure 10-1: US – Estimated Cancer Care Expenditure by Healthcare (US$ Billion), 2019 & 2026
Figure 1-1: Natural Antigen Presentation by Antigen Presenting Cells
Figure 1-2: Artificial Immune Modulation Antigen Presentation
Figure 1-3: Types of Therapies Based on Immunotherapy Principle
Figure 1-4: Results of Antigen Presentation on T-Cells by Antigen Presenting Cells
Figure 1-5: US – Population of Men & Women Living with Auto-Immune Diseases (Million), 2020
Figure 1-6: US – Cancer Statistics (Million), 2019
Figure 2-1: Different Configurations Used in Nano Bio Materials for Medical or Biological Issues
Figure 2-2: Applications of Nanotechnology in Medicines
Figure 2-3: Potential Contribution of Nanoparticles to Immunotherapies
Figure 3-1: Synthetic Immunology Working on Immune Cells
Figure 3-2: Potential Addition of Functions to Engineered Immune Cells
Figure 3-3: Synthetic Immunology & Artificial Immune Modulation Combination
Figure 4 1: Representation of Immune System Attacking Cancer Cells with the help of Antigen Presenting Cells
Figure 4-2: North America – Population above 65 Years of Age (Million), 2018
Figure 4-3: Artificial Immune Modulation Against Cancer
Figure 4-4: US- Auto-Immune Diseases Statistics (Million), 2020
Figure 4-5: Potential Applications for Artificial Immune Modulation in Medical Field
Figure 5-1: Benefits of Clinical Trials in Medical World
Figure 5-2: Enrichment & Expansion Process Overview for Artificial Immune Modulation Platform
Figure 6-1: Ongoing Clinical Trials for Artificial Immune Modulation Platform by NexImmune
Figure 6-2: Robust Pipeline for Artificial Immune Modulation Products
Figure 6-3: US – Estimated Acute Myeloid Leukemia Statistics, 2020
Figure 6-4: US – Acute Myeloid Leukemia New Cancer Cases Statistics (%), 2020
Figure 6-5: US – Acute Myeloid Leukemia Deaths Statistics (%), 2020
Figure 6-6: US – Clinical Trial Status for Artificial Immune Modulation, 2020
Figure 6-7: US – Multiple Myeloma Cancer Statistics, 2020
Figure 6-8: US – Multiple Myeloma Cancer Statistics by Gender, 2020
Figure 6-9: US – Clinical Trial Status for Artificial Immune Modulation
Figure 7-1: Recent Trends & Opportunity for Artificial Immune Modulation Growth
Figure 7-2: Global – Total New Cases of Cancers (Million), 2018
Figure 7-3: Global - Total Cancer Deaths (Million), 2018
Figure 7-4: Global – New Cases of Multiple Myeloma, 2018
Figure 7-5: Global – Total Deaths Due to Multiple Myeloma, 2018
Figure 7-6: Clinical Benefits of using Cancer Immunotherapy
Figure 7-7: Global - Cancer Immunotherapeutic Market (US$ Billion), 2018-2026
Figure 7-8: US – Active, Not Recruiting Clinical Trials for Immunotherapy vs. Other Cancer Treatment Methods, 2020
Figure 7-9: Pharmaceutical Companies Investing in Immunotherapy Development
Figure 7-10: Global - Roche’s Total Immunological Products Sales (US$ Million), 2015 - 2019
Figure 7-11: Global – Roche Group Sales Increment (%), 2016 - 2019
Figure 7-12: Global – Eli Lilly’s Total Immunological Product Sales (US$ Million), 2017 - 2019
Figure 7-13: Global – Eli Lilly’s Increase in Immunology Revenue due to Taltz (%), 2018 & 2019
Figure 7-14: Potential Combinations for Artificial Immune Modulation
Figure 8-1: Global – CAR-T Cell Therapy Drug Kymriah Treatment Cost vs. Drug Cost (US$ Million), 2020
Figure 8-2: US – Price of CAR-T Cell Therapy Products (US$), 2020
Figure 8-3: Global – Kymriah Total Sales (US$ Million), 2018 & 2019
Figure 8-4: Global – Yescarta Total Sales (US$ Million), 2018 & 2019
Figure 8-5: US – TIL Immunotherapy Minimum & Maximum Treatment Price (US$), 2020
Figure 8-6: Immunotherapy Price Comparison
Figure 8-7: AIM Therapy – Minimum & Maximum Treatment Price Estimates (US$), 2026
Figure 9-1: Cancer Driver for Artificial Immune Modulation Market
Figure 9-2: Potential Drivers for Artificial Immune Modulation
Figure 9-3: Challenges Associated with Artificial Immune Modulation
Figure 10-1: US – Estimated Cancer Care Expenditure by Healthcare (US$ Billion), 2019 & 2026
